Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first disease progression (PD) in patients with metastatic colorectal cancer (mCRC) previously treated with BEV-based therapy: Outcomes according to KRAS status and first-line CT backbone in the ML18147 study.

Kubicka, S, Greil, R, Andre, T, Bennouna, J, Sastre, J, Van Cutsem, E, Von Moos, R, Osterlund, PJ, Hegde, P, Sersch, MA, Osborne, S, Hermann, F, Arnold, D